Tal Gefen (PhD) is a lab manager and research associate at Naama Geva-Zatorsky’s lab “Microbiome – Host interaction”, Technion, Israel. Tal has graduated the Hebrew university of Jerusalem, where he conducted a research focusing on immunogenicity of therapeutic proteins. Later, as a postdoc under the guidance of Professor Eli Gilboa at University of Miami, he specialized in cancer immunotherapy and developed a novel molecule for the inhibition of checkpoint blockage via the TIM-3 receptor, expressed on exhausted T cells. At the Geva-Zatorsky’s lab, he is mainly focusing on microbial-immunological technology integration, development, and projects management.